Other · developed by Genprex
DOTAP:Chol-TUSC2 is a liposome complex carrying the TUSC2 gene, delivered intravenously at a dose of 0.045 mg/kg on day 1 of each 21-day cycle. It is studied in lung cancer, including non-small-cell lung carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01455389 | Phase 1/2 | Lung Cancer | Terminated | GNPX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Lung Cancer
Updated Nov 15, 2026. Something wrong or missing? Report it on the GNPX page.
See GNPX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GNPX catalysts and pipeline →